Dale N. Gerding

Q: What Schools Are Affiliated With Dale N. Gerding

Dale N. Gerding is affiliated with the following schools: Emory University, University of Minnesota, Loyola University Chicago

Dale N. Gerding's AcademicInfluence.com Rankings

Dale N. Gerding

Philosophy

#4256

World Rank

#6714

Historical Rank

Logic

#1760

World Rank

#2597

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Dale N. Gerding's Degrees

Doctorate Medicine University of Illinois College of Medicine

Why Is Dale N. Gerding Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dale N. Gerding's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) (2010) (2616)
An epidemic, toxin gene-variant strain of Clostridium difficile. (2005) (2053)
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship (2007) (1982)
Burden of Clostridium difficile infection in the United States. (2015) (1974)
Clostridium difficile infection: new developments in epidemiology and pathogenesis (2009) (1354)
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. (2007) (1306)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). (2018) (1149)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). (2018) (1083)
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. (1997) (842)
Strategies to Prevent Surgical Site Infections in Acute Care Hospitals (2008) (797)
Toxin B is essential for virulence of Clostridium difficile (2009) (736)
Combating antimicrobial resistance: policy recommendations to save lives. (2011) (655)
Emergence and global spread of epidemic healthcare-associated Clostridium difficile (2012) (640)
PROSPECTIVE RANDOMISED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHOEA AND COLITIS (1983) (625)
Strategies to Prevent Central Line–Associated Bloodstream Infections in Acute Care Hospitals (2008) (617)
Treatment with monoclonal antibodies against Clostridium difficile toxins. (2010) (611)
Clinical recognition and diagnosis of Clostridium difficile infection. (2008) (561)
Survival of influenza viruses on environmental surfaces. (1982) (535)
Strategies to Prevent Catheter-Associated Urinary Tract Infections in Acute Care Hospitals (2008) (535)
Clostridium difficile--associated diarrhea. (1998) (529)
Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. (1992) (485)
Strategies to Prevent Ventilator-Associated Pneumonia in Acute Care Hospitals (2008) (465)
Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium (2009) (447)
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. (2014) (430)
A mouse model of Clostridium difficile-associated disease. (2008) (411)
Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea (1998) (385)
Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. (2013) (385)
Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. (1999) (382)
Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. (1986) (369)
Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. (1992) (366)
Nosocomial Clostridium difficile colonisation and disease (1990) (361)
Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. (2009) (350)
Comparison of Seven Techniques for Typing International Epidemic Strains of Clostridium difficile: Restriction Endonuclease Analysis, Pulsed-Field Gel Electrophoresis, PCR-Ribotyping, Multilocus Sequence Typing, Multilocus Variable-Number Tandem-Repeat Analysis, Amplified Fragment Length Polymorphis (2007) (349)
Measures to control and prevent Clostridium difficile infection. (2008) (348)
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection (2017) (342)
Clostridium Difficile-Associated Diarrhea and Colitis (1995) (341)
Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals (2008) (337)
Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. (1990) (330)
Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. (2007) (329)
Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. (2020) (304)
Acquisition of Clostridium difficile and Clostridium difficile-Associated Diarrhea in Hospitalized Patients Receiving Tube Feeding (1998) (300)
Human Hypervirulent Clostridium difficile Strains Exhibit Increased Sporulation as Well as Robust Toxin Production (2010) (299)
Ten Years of Prospective Clostridium difficile-Associated Disease Surveillance and Treatment at the Minneapolis VA Medical Center, 1982–1991 (1994) (288)
Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. (2015) (272)
Executive Summary: A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals (2008) (259)
Incidence of infection in systemic lupus erythematosus. (1974) (258)
Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital (1991) (258)
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). (2010) (255)
Clostridium difficile binary toxin CDT (2013) (253)
In Vitro Activities of 15 Antimicrobial Agents against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983 to 2004 (2007) (237)
Toxinotype V Clostridium difficile in Humans and Food Animals (2008) (237)
Comparative Phylogenomics of Clostridium difficile Reveals Clade Specificity and Microevolution of Hypervirulent Strains (2006) (235)
Decrease in Nosocomial Clostridium difficileAssociated Diarrhea by Restricting Clindamycin Use (1994) (232)
Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. (2006) (227)
Impact of Strain Type on Detection of Toxigenic Clostridium difficile: Comparison of Molecular Diagnostic and Enzyme Immunoassay Approaches (2010) (219)
Strategies to Prevent Transmission of Methicillin-Resistant Staphylococcus aureus in Acute Care Hospitals (2008) (204)
Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections (2015) (203)
Osteomyelitis in the feet of diabetic patients. Long-term results, prognostic factors, and the role of antimicrobial and surgical therapy. (1987) (196)
Treatment of Clostridium difficile infection. (2008) (193)
Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. (2004) (191)
Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals: 2014 Update (2014) (191)
Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy (1992) (190)
Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. (1989) (181)
Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile (2008) (180)
Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. (2012) (180)
Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. (2004) (175)
A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. (2005) (175)
Foot infections in diabetic patients: the role of anaerobes. (1995) (174)
NAP1 strain type predicts outcomes from Clostridium difficile infection. (2014) (168)
Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems (1993) (167)
Fatal Pseudomembranous Colitis Associated with a Variant Clostridium difficile Strain Not Detected by Toxin A Immunoassay (2001) (163)
Effectiveness of Alcohol-Based Hand Rubs for Removal of Clostridium difficile Spores from Hands (2010) (154)
Multilocus Variable-Number Tandem-Repeat Analysis for Investigation of Clostridium difficile Transmission in Hospitals (2006) (154)
Corynebacterium equi: a review of 12 cases of human infection. (1983) (153)
Pseudomonas infection of the biliary system resulting from use of a contaminated endoscope. (1987) (146)
A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 Updates (2014) (143)
Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. (1989) (140)
Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin (2012) (139)
Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. (1994) (139)
Increased dosage requirements of gentamicin in burn patients. (1976) (130)
Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. (2009) (126)
Breakthroughs in the treatment and prevention of Clostridium difficile infection (2016) (123)
Comparison of restriction endonuclease analysis, ribotyping, and pulsed-field gel electrophoresis for molecular differentiation of Clostridium difficile strains (1994) (120)
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance Guidelines for the Prevention of Antimicrobial Resistance in Hospitals (1997) (118)
Frequency of Binary Toxin Genes among Clostridium difficile Strains That Do Not Produce Large Clostridial Toxins (2003) (117)
Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. (2007) (115)
Effectiveness of Liquid Soap vs. Chlorhexidine Gluconate for the Removal of Clostridium difficile from Bare Hands and Gloved Hands (1994) (114)
Does antibiotic restriction prevent resistance? (1996) (113)
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence (2018) (113)
Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization. (1990) (112)
Infection of hamsters with epidemiologically important strains of Clostridium difficile. (2001) (111)
Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? (1997) (111)
Revised nomenclature of Clostridium difficile toxins and associated genes. (2005) (107)
Clostridium difficile Infection Among Children Across Diverse US Geographic Locations (2014) (106)
Surface-Layer Protein A (SlpA) Is a Major Contributor to Host-Cell Adherence of Clostridium difficile (2013) (104)
A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 Updates. (2014) (103)
Comparison of Strain Typing Results for Clostridium difficile Isolates from North America (2011) (101)
Effect of nucleic acid amplification testing on population-based incidence rates of Clostridium difficile infection. (2013) (100)
Serious staphylococcal infections with strains tolerant to bactericidal antibiotics. (1979) (99)
The search for good antimicrobial stewardship. (2001) (97)
Fecal incontinence in hospitalized patients who are acutely ill. (2000) (97)
Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? (2005) (97)
The association between Staphylococcus aureus bacteremia and bacteriuria. (1978) (97)
Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection (2011) (97)
Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. (1992) (95)
DNA fingerprinting by pulsed field gel electrophoresis and ribotyping to distinguish Pseudomonas cepacia isolates from a nosocomial outbreak (1991) (94)
Colonization for the Prevention of Clostridium difficile Disease in Hamsters (2002) (94)
Evaluation of an Oral Suspension of VP20621, Spores of Nontoxigenic Clostridium difficile Strain M3, in Healthy Subjects (2012) (94)
Disease associated with Clostridium difficile infection. (1989) (93)
Colonization for the prevention of Clostridium difficile disease in hamsters. (1999) (92)
Wide diversity of Clostridium difficile types at a tertiary referral hospital. (1994) (90)
Detection of asymptomatic Clostridium difficile carriage by an alcohol shock procedure (1989) (89)
Renal Failure and Leukocytosis Are Predictors of a Complicated Course of Clostridium difficile Infection if Measured on Day of Diagnosis (2012) (88)
Comparative Activities of the Oxa-β-Lactam LY127935, Cefotaxime, Cefoperazone, Cefamandole, and Ticarcillin Against Multiply Resistant Gram-Negative Bacilli (1980) (88)
Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center. (1985) (87)
Global Epidemiology of Clostridium difficile Infection in 2010 (2010) (87)
Spore Formation and Toxin Production in Clostridium difficile Biofilms (2014) (84)
Clinical and endoscopic findings in patients early in the course of clostridium difficile-associated pseudomembranous colitis. (1985) (84)
Management of Clostridium difficile infection: thinking inside and outside the box. (2010) (83)
Comparison of the VIDAS Clostridium difficile toxin A immunoassay with C. difficile culture and cytotoxin and latex tests (1992) (82)
International Typing Study of Toxin A-Negative, Toxin B-Positive Clostridium difficile Variants (2003) (81)
Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection (2018) (80)
Toxin Gene Analysis of a Variant Strain ofClostridium difficile That Causes Human Clinical Disease (2000) (80)
Immunoblots and plasmid fingerprints compared with serotyping and polyacrylamide gel electrophoresis for typing Clostridium difficile (1988) (78)
Nosocomial Multiply Resistant Klebsiella pneumoniae: Epidemiology of an Outbreak of Apparent Index Case Origin (1979) (77)
MBCs for Staphylococcus aureus as determined by macrodilution and microdilution techniques (1984) (74)
Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study (2017) (74)
Onset of Symptoms and Time to Diagnosis of Clostridium difficile–Associated Disease Following Discharge From an Acute Care Hospital (2007) (74)
Nontoxigenic Clostridium difficile Protects Hamsters against Challenge with Historic and Epidemic Strains of Toxigenic BI/NAP1/027 C. difficile (2013) (73)
New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. (2009) (73)
Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007. (2009) (73)
Influence of protein binding of antibiotics on serum pharmacokinetics and extravascular penetration: clinically useful concepts. (1980) (72)
Cleaning and disinfection of fiberoptic endoscopes: evaluation of glutaraldehyde exposure time and forced-air drying. (1982) (71)
Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals: 2014 Update (2014) (71)
Physical Characterization of Ten R Plasmids Obtained from an Outbreak of Nosocomial Klebsiella pneumoniae Infections (1979) (71)
The epidemiology of Clostridium difficile infection inside and outside health care institutions. (2015) (71)
Multicenter typing comparison of sporadic and outbreak Clostridium difficile isolates from geographically diverse hospitals. (1997) (70)
Use of an anaerobic collection and transport swab device to recover anaerobic bacteria from infected foot ulcers in diabetics. (1995) (68)
Effect of the ratio of surface area to volume on the penetration of antibiotics in to extravascular spaces in an in vitro model. (1982) (68)
Optimal methods for identifying Clostridium difficile infections. (1993) (67)
Tissue penetration of the new quinolones in humans. (1989) (67)
Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection (2015) (66)
Effectiveness of Hand Hygiene for Removal of Clostridium difficile Spores from Hands (2013) (64)
Antimicrobial resistance among enterococci (1991) (64)
Clostridium difficile 30 years on: what has, or has not, changed and why? (2009) (63)
Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease (1995) (63)
Results of a prospective, 18-month clinical evaluation of culture, cytotoxin testing, and culturette brand (CDT) latex testing in the diagnosis of Clostridium difficile-associated diarrhea. (1988) (62)
Risk Factors for Community-Associated Clostridium difficile Infection in Adults: A Case-Control Study (2015) (62)
Antimicrobial Cycling: Lessons Learned From the Aminoglycoside Experience (2000) (61)
Staphylococcus aureus bacteriuria. (1979) (60)
Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis. (2010) (60)
Cephalosporin and Aminoglycoside Concentrations in Peritoneal Capsular Fluid in Rabbits (1976) (59)
In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp (1984) (58)
Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. (2003) (57)
Molecular epidemiology of Clostridium difficile over the course of 10 years in a tertiary care hospital. (2009) (57)
Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection (2016) (55)
Infection of hamsters with historical and epidemic BI types of Clostridium difficile. (2007) (54)
Screening and treatment of infections caused by resistant enterococci (1991) (53)
Characterization of a nosocomial Clostridium difficile outbreak by using plasmid profile typing and clindamycin susceptibility testing. (1988) (52)
U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin (2015) (52)
Comparison of arbitrarily primed PCR with restriction endonuclease and immunoblot analyses for typing Clostridium difficile isolates (1995) (51)
Fourteen-Genome Comparison Identifies DNA Markers for Severe-Disease-Associated Strains of Clostridium difficile (2011) (51)
Multilocus Variable-Number Tandem-Repeat Analysis and Multilocus Sequence Typing Reveal Genetic Relationships among Clostridium difficile Isolates Genotyped by Restriction Endonuclease Analysis (2009) (50)
Treatment and long-term follow-up of foot infections in patients with diabetes or ischemia: a randomized, prospective, double-blind comparison of cefoxitin and ceftizoxime. (1987) (50)
Analysis of Bacterial Communities during Clostridium difficile Infection in the Mouse (2015) (50)
Medium-Dependent Variation in Bactericidal Activity of Antibiotics Against Susceptible Staphylococcus aureus (1978) (50)
A Simulation-Based Assessment of Strategies to Control Clostridium Difficile Transmission and Infection (2013) (50)
Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model. (1986) (50)
A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 Updates (2014) (49)
Metronidazole resistance in Clostridium difficile. (2000) (49)
Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. (2009) (49)
Detection of Clostridium difficile toxins A (enterotoxin) and B (cytotoxin) in clinical specimens. Evaluation of a latex agglutination test. (1986) (49)
Burden of Nursing Home-Onset Clostridium difficile Infection in the United States: Estimates of Incidence and Patient Outcomes (2016) (49)
Antibiotic concentrations in ascitic fluid of patients with ascites and bacterial peritonitis. (1977) (49)
Protein-losing enteropathy is associated with Clostridium difficile diarrhea but not with asymptomatic colonization: a prospective, case-control study. (1996) (48)
Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027 (2015) (48)
Prediction of Cefazolin Penetration into High- and Low-Protein-Containing Extravascular Fluid: New Method for Performing Simultaneous Studies (1978) (47)
An Economic Analysis of Strategies to Control Clostridium Difficile Transmission and Infection Using an Agent-Based Simulation Model (2016) (46)
Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines. (2012) (45)
Comparative Genome Analysis and Global Phylogeny of the Toxin Variant Clostridium difficile PCR Ribotype 017 Reveals the Evolution of Two Independent Sublineages (2016) (45)
Epidemiology and outcome of Clostridium difficile infection and diarrhea in HIV infected inpatients. (2002) (44)
Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in Stool (2015) (43)
Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies (2014) (43)
Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colonization. (2012) (42)
Efficacy of routine fiberoptic endoscope cleaning and disinfection for killing Clostridium difficile. (1986) (41)
Standardization of a preparative ultracentrifuge method for quantitative determination or protein binding of seven antibiotics. (1977) (40)
Vancomycin Taper and Pulse Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection (2017) (40)
Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences. (2013) (39)
Comparison of cycloserine-cefoxitin-fructose agar (CCFA) and taurocholate-CCFA for recovery of Clostridium difficile during surveillance of hospitalized patients. (1997) (39)
Laboratory detection of Clostridium difficile. A comparison of media and incubation systems. (1995) (38)
The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases (2016) (37)
gyrA mutations in ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus from Indiana, Minnesota, and Tennessee. (1991) (36)
Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model (1984) (35)
Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom. (2010) (35)
Chapter 8 – Enterotoxemic Infections (1997) (34)
Transmission of Clostridium difficile from asymptomatically colonized or infected long-term care facility residents (2018) (34)
Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods. (1987) (34)
Staphylococcus aureus and Clostridium difficile cause distinct pseudomembranous intestinal diseases. (2004) (33)
Treatment of Clostridium difficile-associated diarrhea and colitis. (2000) (33)
Favorable prognosis of patients with prosthetic valve endocarditis caused by gram-negative bacilli of the HACEK group. (1988) (33)
Clostridium difficile Infection and Limitations of Markers for Severity in Patients with Hematologic Malignancy (2013) (33)
Prospective study of gram-stained stool smears in diagnosis of Clostridium difficile colitis (1983) (33)
Acceptance of Hepatitis B Vaccine by Hospital Personnel (1985) (33)
Pasteurella multocida peritonitis in hepatic cirrhosis with ascites. (1976) (33)
Molecular Epidemiology of Clostridium difficile Infections in Children: A Retrospective Cohort Study (2015) (32)
In vitro activity of ciprofloxacin combined with azlocillin (1985) (32)
Non-toxigenic Clostridioides (Formerly Clostridium) difficile for Prevention of C. difficile Infection: From Bench to Bedside Back to Bench and Back to Bedside (2018) (32)
Clostridium difficile Outbreak Strain BI Is Highly Endemic in Chicago Area Hospitals (2011) (31)
Gentamicin Intravenous Infusion Rate: Effect on Interstitial Fluid Concentration (1977) (31)
Penetration of tobramycin into infected extravascular fluids and its therapeutic effectiveness. (1977) (31)
Influenza B: hospital activity during a community epidemic. (1983) (31)
Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection with Greater Severity and Higher Recurrence Rates. (2019) (30)
Protection from Clostridium difficile Infection in CD4 T Cell- and Polymeric Immunoglobulin Receptor-Deficient Mice (2013) (30)
Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection (2015) (29)
Lack of evidence for an unmet need to treat Clostridium difficile infection in infants aged <2 years: expert recommendations on how to address this issue. (2015) (29)
Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985. (1986) (29)
Fungal meningitis manifesting as hydrocephalus. (1983) (29)
Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. (2019) (29)
Ascitic Fluid Cephalosporin Concentrations: Influence of Protein Binding and Serum Pharmacokinetics (1978) (29)
Treatment of Pseudomonas endophthalmitis associated with prosthetic intraocular lens implantation. (1979) (28)
Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis (2016) (28)
Clostridium difficile diarrhea and colonization after treatment with abdominal infection regimens containing clindamycin or metronidazole. (1990) (27)
Pleural effusion associated with viral hepatitis. (1971) (27)
Introduction to “A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 Updates” (2014) (26)
Susceptibility of hamsters to human pathogenic Clostridium difficile strain B1 following clindamycin, ampicillin or ceftriaxone administration. (2003) (26)
Nosocomial febrile illnesses in patients on an internal medicine service. (1989) (25)
Effect of method of administration on extravascular penetration of four antibiotics (1982) (25)
Metronidazole Susceptibility in Clostridium difficile Isolates Recovered from Cases of C. difficile -associated Disease Treatment Failures and Successes (1999) (25)
Role of serum protein binding and multiple antibiotic doses in the extravascular distribution of ceftizoxime and cefotaxime (1982) (25)
Natural Clostridioides difficile toxin immunization in colonized infants. (2019) (25)
Enhancement of the in vitro activity of amphotericin B against Aspergillus spp. by tetracycline analogs (1984) (25)
Medical technologists using molecular epidemiology as part of the infection control team. (1993) (24)
The penetration of antibiotics into peritoneal fluid. (1975) (24)
Clostridium difficile infection in 2010: Advances in pathogenesis, diagnosis and management of CDI (2011) (24)
Utility of a Commercial PCR Assay and a Clinical Prediction Rule for Detection of Toxigenic Clostridium difficile in Asymptomatic Carriers (2013) (24)
Diagnosis of Clostridium difficile--associated disease: patient selection and test perfection. (1996) (24)
Sustained Clinical Response as an Endpoint in Treatment Trials of Clostridium difficile-Associated Diarrhea (2012) (24)
Comparison Study of the Kinetics of Ceftizoxime Penetration into Extravascular Spaces with Known Surface Area/Volume Ratio In Vitro and In Vivo in Rabbits (1983) (23)
Effects of method of antibiotic administration on extravascular penetration: cross-over study of cefazolin given by intermittent injection or constant infusion. (1981) (23)
Evaluation of the 24-h API 20A anaerobe system for identification of Clostridium difficile (1984) (23)
Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients (2016) (22)
Comparative genomics analysis of Clostridium difficile epidemic strain DH/NAP11/106. (2018) (22)
Risk Factors for Recurrent Clostridium difficile Infection in Children: A Nested Case-Control Study. (2015) (22)
Clostridium difficile Whole Genome Sequencing Reveals Limited Transmission Among Symptomatic Children: A Single-Center Analysis (2018) (22)
Bacterial agglutination and polyacrylamide gel electrophoresis for typing Clostridium difficile. (1986) (22)
Antibiotic Penetrance of Ascitic Fluid in Dogs (1976) (21)
Introduction to “A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 Updates” (2014) (21)
Acremonium falciforme (Cephalosporium falciforme) mycetoma in a renal transplant patient. (1983) (21)
Ketoconazole and flucytosine alone and in combination against Candida spp. in a neutropenic site in rabbits. (1986) (21)
Difference in the Incidence of Clostridium difficile Among Patients Infected With Human Immunodeficiency Virus Admitted to a Public Hospital and a Private Hospital (2002) (20)
U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016 (2019) (20)
Evaluation of cycloserine-cefoxitin-fructose agar and cycloserine-cefoxitin-fructose broth for recovery of Clostridium difficile from environmental sites (1991) (19)
Clinical and Microbiologic Assessment of Cases of Pediatric Community-associated Clostridium difficile Infection Reveals Opportunities for Improved Testing Decisions (2015) (19)
Frequency of aminoglycoside 6'-N-acetyltransferase among Serratia species during increased use of amikacin in the hospital (1986) (19)
High-pressure liquid chromatographic assay of ceftizoxime with an anion-exchange extraction technique (1982) (19)
Clostridium difficile infection rates and spectrum of disease among peripartum women at one hospital from 2003 to 2007 with molecular typing analysis of recovered Clostridium difficile isolates. (2011) (19)
Influence of protein binding on therapeutic efficacy of cefoperazone (1989) (19)
Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015. (2018) (18)
Editorial: Making Fecal Microbiota Transplantation Easier to Swallow: Freeze-Dried Preparation for Recurrent Clostridium difficile Infections (2017) (18)
Trends in incidence of long‐term‐care facility onset Clostridium difficile infections in 10 US geographic locations during 2011‐2015 (2018) (18)
New Definitions Will Help, but Cultures are Critical for Resolving Unanswered Questions About Clostridium difficile (2007) (18)
Prediction of the concentration of penicillins in ascitic fluid from serum kinetics and protein binding of the antibiotics in serum and ascitic fluid of dogs. (1978) (18)
Diagnosis and Treatment of Clostridium difficile Infection (2016) (18)
Mezlocillin, ceftizoxime, and amikacin alone and in combination against six Enterobacteriaceae in a neutropenic site in rabbits. (1985) (17)
Current and future trends in clostridioides (clostridium) difficile infection management. (2019) (17)
Multihospital Outbreak of Clostridium difficile Infection, Cleveland, Ohio, USA (2010) (17)
Clostridium difficile Infection Among Veterans Health Administration Patients (2015) (17)
Does infection with specific Clostridium difficile strains or clades influence clinical outcome? (2013) (17)
Recurrence of Clostridium difficile infection among veterans with spinal cord injury and disorder. (2014) (17)
Ceftazidime and amikacin alone and in combination against Pseudomonas aeruginosa and Enterobacteriaceae. (1987) (17)
Evaluation of new blood culture processing systems (1984) (17)
Evaluation of Three Newer Methods for Investigating Protein Interactions of Penicillin G (1977) (16)
Improved recovery of microorganisms from patients receiving antibiotics with the antimicrobial removal device. (1983) (16)
Comparative tissue and extravascular fluid concentrations of ceftizoxime. (1982) (16)
Bezlotoxumab Alone and With Actoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients on Standard of Care Antibiotics: Integrated Results of 2 Phase 3 Studies (MODIFY I and MODIFY II) (2015) (16)
Genotypic and phenotypic analysis of Clostridium difficile correlated with previous antibiotic exposure. (2006) (16)
Determination of tolerance to antibiotic bactericidal activity on Kirby-Bauer susceptibility plates. (1980) (15)
Clinical Utility of Laboratory Detection of Clostridium difficile Strain BI/NAP1/027 (2015) (15)
Workshop on Immunizations in Older Adults: Identifying Future Research Agendas (2010) (15)
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial (2022) (15)
Kibdelomycin Is a Potent and Selective Agent against Toxigenic Clostridium difficile (2014) (15)
Measuring the severity of Clostridium difficile infection: implications for management and drug development (2008) (15)
Pharmacokinetics, protein binding, and extravascular distribution of ceftizoxime in normal subjects (1982) (15)
Pharmacokinetics, protein binding, and predicted extravascular distribution of moxalactam in normal and renal failure subjects (1981) (15)
Assay of netilmicin, using enzyme immunoassay for gentamicin (1982) (15)
High-Pressure Liquid Chromatographic Analysis for Quantitation of BMY-28142 and Ceftazidime in Human and Rabbit Serum (1986) (14)
In vitro activity of efrotomycin, ciprofloxacin, and six other antimicrobials against Clostridium difficile. (1987) (14)
Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection. (2020) (14)
Hospital distribution, persistence, and reintroduction of related gentamicin R plasmids (1986) (14)
In vivo and in vitro activity of ciprofloxacin plus azlocillin against 12 streptococcal isolates in a neutropenic site model. (1987) (13)
Aminoglycosides versus beta-lactams in gram-negative pneumonia. (1991) (13)
Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile. (2009) (13)
Intravenous metronidazole and Clostridium difficile-associated diarrhea or colitis. (1989) (13)
Predominance of a Single Restriction Endonuclease Analysis Group with Intrahospital Subgroup Diversity Among Clostridium difficile Isolates at Two Chicago Hospitals (2002) (12)
Antigen-induced experimental septic arthritis in rabbits after intraarticular injection of Staphylococcus aureus. (1986) (12)
Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones. (2011) (12)
In vitro activities of ureidopenicillins alone and in combination with amikacin and three cephalosporin antibiotics (1984) (11)
GyrA sequence analysis of Staphylococcus aureus and methicillin-resistant S. aureus strains selected, in vitro, for high-level ciprofloxacin resistance. (1993) (11)
Effect of protein binding on simulated intravascular and extravascular kinetics of cefotaxime in an in vitro model (1984) (11)
Cavitary pneumonia associated with tularemia. (1978) (11)
Concomitant Medical Conditions and Therapies Preclude Accurate Classification of Children With Severe or Severe Complicated Clostridium difficile Infection. (2015) (11)
Treatment evaluation of experimental staphylococcal infections: comparison of beta-lactam, lipopeptide, and glycopeptide antimicrobial therapy. (1990) (11)
Whole-genome analysis reveals the evolution and transmission of an MDR DH/NAP11/106 Clostridium difficile clone in a paediatric hospital (2018) (10)
Antimotility agents for the treatment of Clostridium difficile infection: is the juice worth the squeeze? (2009) (10)
Clostridium difficile-associated disease treatment response depends on definition of cure. (2007) (10)
Clostridium difficile plasmid isolation as an epidemiologic tool (1988) (10)
Neutrophil localization in acute and chronic experimental abscesses. (1987) (10)
Fecal Fixation: Fecal Microbiota Transplantation for Clostridium difficile Infection. (2017) (10)
Relation between in vivo abscess localization and in vitro migration and adherence of neutrophils. (1985) (10)
Serum protein binding and extravascular distribution of antimicrobials. (1985) (10)
Differential Immunodetection of Toxin B from Highly Virulent Clostridium difficile BI/NAP-1/027 (2015) (10)
Shea Position Paper CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA AND COLITIS (1999) (9)
Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection (2020) (9)
Host Immune Responses to Clostridioides difficile: Toxins and Beyond (2021) (9)
Occurrence and reproducibility of the "skip" phenomenon in bactericidal testing of Staphylococcus aureus. (1987) (9)
Interaction of cephalosporins with human and canine serum proteins. (1978) (9)
Failure of single doses of cefazolin and cefamandole to penetrate experimental chronic Escherichia coli abdominal abscesses (1980) (9)
International typing study of Clostridium difficile. (2014) (8)
Assay of 27 antimicrobials using a microbiological method. (1983) (8)
Good Antimicrobial Stewardship in the Hospital Fitting, but Flagrantly Flagging (2000) (8)
More than one DNA sequence encodes the 2''-O-adenylyltransferase phenotype (1987) (8)
Is pulsed dosing the answer to treatment of Clostridium difficile infection? (2017) (8)
Comparative efficacy of cefoperazone, cefoperazone plus sulbactam, ciprofloxacin, clindamycin, metronidazole, and penicillin G against anaerobic bacteria in an animal model. (1990) (8)
Prediction of peak penicillin and cephalosporin concentrations in canine serum as derived from in vitro serum and tissue quantitative protein binding (1979) (8)
Evaluation of a Commercial Microdilution System for Quantitative Susceptibility Testing of Aminoglycosides Against Multidrug-Resistant, Gram-Negative Bacilli (1980) (8)
SHEA Conference on Antimicrobial Resistance (2000) (8)
Cephalothin clearance of Staphylococcus aureus from two experimental infection sites in the presence and absence of local phagocytic cells. (1987) (7)
Changing Epidemiology of Clostridium difficile-Associated Disease: Experience and Perception of Infectious Diseases Consultants (2006) (7)
Comparative in vitro activity of BMY-28142 alone and in combination with amikacin against clinical strains of Pseudomonas aeruginosa, Staphylococcus aureus and enterobacteriaceae (1986) (7)
Microdilution aminoglycoside susceptibility testing of Pseudomonas aeruginosa and Escherichia coli: correlation between MICs of clinical isolates and quality control organisms (1985) (7)
Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II. (2019) (7)
599 The Monoclonal Antibody, Bezlotoxumab Targeting C. difficile Toxin B Shows Efficacy in Preventing Recurrent C. difficile Infection (CDI) in Patients at High Risk of Recurrence or of CDI-Related Adverse Outcomes (2016) (7)
Activity of twenty-one antimicrobial agents including l-ofloxacin against quinolone-sensitive and -resistant, and methicillin-sensitive and -resistant Staphylococcus aureus. (1994) (7)
Community-Associated Clostridium difficile Infection among Veterans with Spinal Cord Injury and Disorder (2014) (7)
Chapter 14 – Pathology and Diagnosis of Clostridium difficile Disease (1988) (7)
Treatment of Recurrent Clostridium difficile Infection. (2019) (7)
Editorial Commentary: Whole-Genome Sequencing of Clostridium difficile: Exquisitely Sensitive but Not Yet Optimally Applied. (2016) (7)
The Impact of Recurrent Clostridium difficile Infection on Patients’ Prevention Behaviors (2017) (6)
Treatment of Clostridium difﬁcile Infection (2007) (6)
Correlation between restriction endonuclease analysis and PCR ribotyping for the identification of Clostridioides (Clostridium) difficile clinical strains. (2018) (6)
Staphylococcal endocarditis in narcotic addicts. Diagnosis and treatment. (1975) (6)
Treatment of ciprofloxacin- and ceftizoxime-induced resistant gram-negative bacilli. (1987) (6)
Results from Two Multinational, Randomized, Controlled Trials (2014) (6)
Ciprofloxacin penetration into extravascular spaces in a rabbit model (1984) (6)
Detection of C. difficile toxin A (enterotoxin) (1987) (6)
Effects of biliary obstruction on hepatic clearance of bacteria. (1989) (6)
Toxin A-predominant Pathogenic C. difficile: A Novel Clinical Phenotype. (2020) (5)
Treatment of Clostridioides difficile Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013–2015 (2019) (5)
Epidemiologic Trends in Clostridium difficile Isolate Ribotypes in United States from 2010 to 2014 (2017) (5)
Unique Clindamycin-Resistant Clostridioides difficile Strain Related to Fluoroquinolone-Resistant Epidemic BI/RT027 Strain (2020) (5)
Etiologic diagnosis of acute pneumonia in adults: a growing challenge. (1981) (5)
Effect ofMethodofAdministration onExtravascular Penetration ofFourAntibiotics (1982) (4)
Efficacy of Bezlotoxumab in Patients Infected with Strains of Clostridium difficile Associated with Poor Outcomes (2016) (4)
In vitro activity of LY 264826 compared with that of vancomycin against 100 clinical isolates each of methicillin-resistant Staphylococcus aureus and Clostridium difficile (1990) (4)
Neutrophil chemotaxis and adherence in vitro and localization in vivo in rabbits with Staphylococcus aureus abscesses. (1989) (4)
245 – Clostridium difficile Infection (2015) (4)
Epidemiologic trends in Clostridioides difficile isolate ribotypes in United States from 2011 to 2016. (2020) (4)
Immunoblots andPlasmid Fingerprints ComparedwithSerotyping andPolyacrylamide GelElectrophoresis forTyping Clostridium difficile (1988) (4)
Alterations in Microbial Diversity are Associated with Treatment Success with RBX2660, A Microbiota-Based Drug for the Prevention of Recurrent Clostridium Difficile Infection: Results from Punch CD 2, A Randomized Doubleblind Placebo-Controlled Trial (2017) (3)
Correction for Cairns et al., “Comparative Genome Analysis and Global Phylogeny of the Toxin Variant Clostridium difficile PCR Ribotype 017 Reveals the Evolution of Two Independent Sublineages” (2017) (3)
Identification of patients at risk of Clostridioides difficile infection for enrollment in vaccine clinical trials. (2020) (3)
Efficacy of bezlotoxumab in trial participants infected with Clostridioides difficile strain BI associated with poor outcomes. (2020) (3)
Reply to Fabre et al. (2018) (3)
COMPARISON OF THE VIDAS C. DIFFICILE TOXIN A WITH C.DIFFICILE CULTURE AND CYTOTOXIN AND LATEX TESTS (1992) (3)
Is pediatric Clostridium difficile infection associated with prior antibiotic exposure? (2014) (3)
Use of technetium-99m methylene diphosphonate and gallium-67 citrate scans after intraarticular injection of Staphylococcus aureus into knee joints of rabbits with chronic antigen-induced arthritis. (1986) (3)
Treatment of pulmonary sporotrichosis. (1986) (3)
Clostridium difficile Infection: Results of an International Web-Based Surveillance Project (2009) (3)
Update on antibiotics I. (1979) (3)
Prediction of peak penicillin and cephalosporin concentrations in canine serum as derived from in vitro serum and tissue quantitative protein binding. (1979) (3)
Healthcare facility-onset, healthcare facility-associated Clostridioides difficile infection in Veterans with spinal cord injury and disorder (2019) (3)
Efficacy of bezlotoxumab in patients receiving metronidazole, vancomycin, or fidaxomicin for treatment of Clostridium difficile infection (CDI) (2016) (3)
BASIC—ALIMENTARY TRACT A Mouse Model of Clostridium difficile-Associated Disease (2008) (3)
Complete Genome Sequence of Clostridioides difficile Epidemic Strain DH/NAP11/106/ST-42, Isolated from Stool from a Pediatric Patient with Diarrhea (2017) (3)
Asymptomatic hepatitis B carriers in a family. (1981) (3)
The Relative Role of Toxins A and B in the Virulence of Clotridioides difficile (2020) (3)
Extravascular penetration of tobramycin and netilmicin in a subcutaneous visking chamber model in rabbits (1983) (2)
Research Agenda for Microbiome Based Research for Multidrug-resistant Organism Prevention in the Veterans Health Administration System (2018) (2)
Rifaximin Chaser Following Standard Therapeutic Cocktail for Breaking the Cycle of Multiple C. difficile Diarrhea Recurrences: 521 (2006) (2)
Epidemic Strains of Clostridium difficile: REA, PFGE, PCR- (2007) (2)
Microbiota or placebo after antimicrobial therapy for recurrent Clostridioides difficile at home: A clinical trial with novel home-based enrollment (2021) (2)
Microbiome Profile is Distinct in Patients with Successful Response to Microbiota-Based Drug RBX2660 Relative to Placebo Responders (2017) (2)
Antibacterial activity of cefoperazone and cefoperazone plus sulbactam in a neutropenic site model. (1991) (2)
Diagnosis of Clostridium difficile Colitis (1996) (2)
Tu1880 – Durable Freedom from Clostridium Difficile Infection Recurrence and Microbiome Restoration During Six-Month Follow-Up For a Phase 1 Clinical Trial of Rbx7455?An Investigational Room Temperature-Stable, Oral Microbiotabased Therapeutic (2019) (2)
A Tapered-Pulsed Fidaxomicin Regimen following Treatment in Patients with Multiple Clostridioides difficile Infection Recurrences. (2021) (2)
Absence of toxin gene transfer from Clostridioides difficile strain 630Δerm to nontoxigenic C. difficile strain NTCD-M3r in filter mating experiments (2022) (2)
PROTEIN BINDING AND ANTIBIOTIC CONCENTRATIONS (1978) (2)
751b Phase II Efficacy of Human Monoclonal Antibody Treatment to Prevent C. difficile Recurrence (2009) (2)
Beta-hemolytic streptococcal bacteremia in adults: association with cold weather in Minnesota. (1981) (2)
Restriction Endonuclease Analysis Typing of Clostridium difficile Isolates. (2016) (2)
Metronidazole Resistance inHelicobacter pylori (1999) (2)
Sputum antimicrobial levels and clinical outcome in bronchitis. (1991) (2)
Reinforcement of an infection control bundle targeting prevention practices for Clostridioides difficile in Veterans Health Administration nursing homes. (2019) (2)
Problems in diabetic foot care (1988) (2)
Plasmid macroevolution in a nosocomial environment: Demonstration of a persistent molecular polymorphism and construction of a cladistic phylogeny on the basis of restriction data (2004) (2)
Current and Novel Strategies for Therapy (2008) (1)
1638Clostridium difficile Strains Colonizing Long-Term Care Facility (LTCF) Residents are Similar to Strains Causing Infection in both LTCF and Hospital Patients Suggesting a Shared Continuum of Transmission (2014) (1)
Evaluation ofNew BloodCulture Processing Systems (1984) (1)
624 – Comparison of Two Open-Label Trials Demonstrates Similar 6-Month Outcomes for Rbx2660 and Rbx7455—Investigational Microbiota Restoration Therapeutics Administered by Enema Or Oral Capsules for Preventing Recurrent Clostridium Difficile Infections (2019) (1)
Restriction Endonuclease (REA) Typing of Clostridium difficile Isolates from South America (1999) (1)
Screening andTreatment ofInfections Causedby Resistant Enterococci (1991) (1)
LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections (2019) (1)
Guideline Recommendations: Optimal Timing of Publication and Resulting Rate of Adoption. (2020) (1)
Deﬁning the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difﬁcile Infections (2015) (1)
Introduction to the special issue on Clostridium difficile. (2009) (1)
In-111 Pseudomonas aeruginosa: A simple method of labeling live bacteria with a gamma-emitting radioisotope (2004) (1)
Altering the Microbiome: Patients With a Successful Outcome Following Microbiota-Based RBX2660 Treatment Trend Toward Human Microbiome Project Healthy Subjectsʼ Profile: 173 (2017) (1)
Tu1883 - A Lyophilized, Non-Frozen, Oral Microbiota-Based Drug RBX7455 is Safe, Reduces Clostridium Difficile Infection Recurrence, and Restores the Microbiome (2018) (1)
Defining optimal treatment for recurrent Clostridioides difficile infection (OpTION study): A randomized, double-blind comparison of three antibiotic regimens for patients with a first or second recurrence. (2022) (1)
Diagnosis and Treatment of Clostridium difficile Infection (CDI) (2018) (1)
RBX7455 - a Non-Frozen, Lyophilized, Oral Microbiota Reduces Clostridium difficileInfection Recurrence and Restores Patients‘ Microbiomes Presidential Poster Award (2018) (1)
Introduction: antimicrobial penetration into respiratory secretions. (1991) (1)
Quality of Life Increased After Treatment for Participants in a Phase 2B Randomized, Double-Blinded, Placebo-Controlled Clinical Trial of RBX2660 for Preventing Recurrent Clostridium difficile Infections (2018) (1)
Clindamycin-Resistant Clostridium difficile (2001) (1)
Clostridial Infections (2012) (1)
Interstitial concentration of antibiotics. (1981) (1)
Clostridium difficile Disease: Is Resistance Affecting Its Epidemiology? (2006) (1)
Treatment of Clostridium difficile Infection in 10 US Geographical Locations, 2013–2014 (2016) (1)
Effect of endogenous Clostridium difficile toxin antibodies on recurrence of C. difficile infection (2020) (1)
Unintended Consequences of Antimicrobial Use: Clostridium difficile -Associated Diarrhea (2005) (0)
Physiology and Pharmacology of Antibiotics (2001) (0)
Isolation, In-111 labeling, and abscess detection efficiency of rabbit polymorphonuclear leukocytes (PMN) from blood and peritoneal fluid (1984) (0)
Oral Fluoroquinolone Therapy for Clostridium difficile Enterocolitis-Reply (1988) (0)
797. Management of Patients with Multiple Clostridioides difficile Infection Recurrences using a Tapered-Pulsed Fidaxomicin Strategy (2020) (0)
Earlier Use of Vancomycin Taper and Pulse (VAN-TP) is More Effective for Managing Clostridium difficile Infection (CDI) Recurrences (2015) (0)
Introduction: antimicrobial penetration into respiratory secretions. (1991) (0)
1496. Bezlotoxumab Administered at the End of a Suppressive Drug Regimen for Patients with Multiply Recurrent Clostridioides difficile Infection (2019) (0)
Whole Genome Analysis Reveals the Evolution and Transmission of a Multidrug-Resistant DH/NAP11/106 Clostridium difficile Clone in a Pediatric Hospital (2017) (0)
Convener Clostridium difficile: Have We Reached Bottom Yet? (2008) (0)
Human Hypervirulent Clostridium difﬁcile Strains Exhibit Increased Sporulation as Well as Robust Toxin Production (cid:1) (2010) (0)
529Frequent Transmission of Clostridium Difficile by Asymptomatically Colonized Long-term Care Facility Residents during Hospital Admissions (2014) (0)
Protection from Clostridium difﬁcile Infection in CD4 T Cell- and Polymeric Immunoglobulin Receptor-Deﬁcient Mice (2014) (0)
Adaptive immunity in the mouse model of Clostridium difficile infection (43.4) (2012) (0)
Comparison of the Risk of Recurrent Clostridioides Difficile Infections Among Patients in 2018 Versus 2013. (2022) (0)
Treatment of Staphylococcal Infections-Reply (1980) (0)
Crossover study of extravascular penetration of netilmicin and tobramycin in a rabbit chamber model (1981) (0)
974The Clinical and Molecular Epidemiology of Pediatric Clostridium difficile Infection: Predominance of Restriction Endonuclease Analysis (REA) Group DH (2014) (0)
Risk Factors for Clostridium difficile Infection Recurrence (2015) (0)
Effectiveness and tolerance to highly concentrated vs conventional TPN formulas. (1993) (0)
DIAGNOSIS OF CLOSTRIDIUM DIFFICILE COLITIS. AUTHORS' REPLY (1996) (0)
Cadazolid for the treatment of Clostridium difficile infection: results of two double- blind, double-dummy, non-inferiority, randomised controlled phase 3 trials (2019) (0)
1013 - The Microbiota-Based Drug Rbx2660 is Efficacious and Safe in Patients with Recurrent Clostridium Difficile Infections: Results from 2 Controlled Clinical Trials (2018) (0)
SHEA Abstracts (1992) (0)
Serratia Species During Increased UseofAmikacin intheHospital (1986) (0)
IFFICILE FROM B ARE H ANDS AND G LOVED H ANDS (2014) (0)
497. Identification of Patients at Risk of Clostridium difficile Infection for Enrollment in Vaccine Clinical Trials (2018) (0)
Reply to Million et al. (2018) (0)
beta-Lactamase-positive Staphylococcus epidermidis (CNS3017) no longer that organism. (1994) (0)
ICE volume 36 issue 9 Cover and Front matter (2015) (0)
Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantiﬁcation of Clostridium difﬁcile Toxins in Stool (2015) (0)
Mo1949 ONE AND DONE? EVALUATION OF EFFICACY FROM A SINGLE ADMINISTRATION OF INVESTIGATIONAL MICROBIOTA-BASED DRUG RBX2660 FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: COMPARISON TO SINGLE-ADMINISTRATION FECAL MICROBIOTA TRANSPLANT IN PUBLISHED TRIALS (2020) (0)
Detection of factitious fever. Use of the electronic thermometer. (1977) (0)
Redefining Clostridioides difficile infection antibiotic response and clinical outcomes. (2023) (0)
The 17th Richard J. Duma/NFID Annual News Conference Webinar on Infectious Diseases (2012) (0)
Protecting Patients from Clostridium difficile Infection: What is the Key Focus for Prevention? (2014) (0)
Current Therapies for C. difficile Disease (2007) (0)
Treatment of staphylococcal infections. (1980) (0)
Antimicrobial Use Management in the Control of Hospital-Acquired Infections (2003) (0)
Diagnosis of pneumonia. (1988) (0)
2565. Initial and Recurrent Episodes of Clostridioides difficile: Online Education as a Tool to Improve Management Strategies (2019) (0)
Protein Binding, andExtravascular Distribution ofCeftizoxime inNormalSubjects (1982) (0)
Cure is the Best Prevention: Eliminating Relapse of C. difficile Infection (2014) (0)
Reply to Drekonja (2010) (0)
1665. Potential underreporting of treated patients using a Clostridioides difficile testing algorithm that screens with a nucleic acid amplification test (2022) (0)
1669. A US Based National Surveillance Study for the Susceptibility and Epidemiology of Clostridioides difficile Associated Diarrheal Isolates with Special Reference to Ridinilazole: 2020-2021 (2022) (0)
In Vitro Activity of Nitazoxanide, Tizoxanide, Metronidazole, and Vancomycin Against 110 Unique Toxigenic Clostridium difficile Clinical Isolates (2006) (0)
Diagnosis of Clostridium difficile-related disease. (1988) (0)
Association between changes in plasmid content or outer membrane proteins and increased susceptibility to beta-lactam or aminoglycoside antibiotics among Pseudomonas aeruginosa after in vitro and in vivo exposure to ciprofloxacin (1990) (0)
Acquisition of methicillin-resistantStaphylococcus aupeus (MRSA) on two long term care wards (1993) (0)
Present and Future Management Options for Clostridium difficile Infection (2009) (0)
Cleanliness in Long Term Care Facilities and Clostridium difficile Infection (CDI) (2016) (0)
403. Strain Epidemiology of Clostridioides difficile across Three Geographically Distinct Medical Centers in Chicago (2022) (0)
Effectiveness of Twenty Germicides Against Five Strains of C. difficile spores, With and Without Calf Serum, at Several Exposure Times (2020) (0)
NOTES Evaluation ofthe24-hAPI20AAnaerobe SystemforIdentification ofClostridium dijficile (1984) (0)
Influence ofProtein Binding on Therapeutic Efficacy ofCefoperazone (1989) (0)
Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or Vancomycin (2023) (0)
New Strategies for Clostridium difficile Infection: Needed and Soon? (2006) (0)
asso-Detection of Clostridium difficile Toxins A (enterotoxin) and B (cytotoxin) in Clinical Specimens Evaluation of a Latex Agglutination Test (2016) (0)
976. Clostridium difficile Colonization Molecular Epidemiology and Anti-toxin Serological Responses in Healthy Infants: A Prospective Cohort Study (2018) (0)
304 – Clostridial Infections (2012) (0)
C. difficile adherence is inhibited by pre-incubating bacteria with anti-SlpA antiserum. (2013) (0)
Clinical News. (2016) (0)
The Challenging Conundrum of Diagnosing and Managing Clostridium difficile Infection (2017) (0)
Labeling of pseudomonas aeruginosa with In-111-oxine (1984) (0)
2822 Twelve-Month Durability of Microbiota-Based Drug RBX2660 for Preventing Clostridioides difficile Infection (CDI) Is Not Associated With Patient Demographics: Sub-Population Analysis of a Phase 2 Open-Label Study (2019) (0)
MBCs for Staphylococcus aureus as Determined by Macrodilution and Microdilution Techniques (1984) (0)
Reply to Collins and Riley. (2018) (0)
Effect ofProtein Binding onSimulated Intravascular and Extravascular Kinetics ofCefotaxime inan InVitro Model (1984) (0)
Sequential introduction of a multistep testing algorithm and nucleic acid amplification testing leading to an increase in Clostridioides difficile detection and a trend toward increased strain diversity (2020) (0)
Fourteen-Genome Comparison Identiﬁes DNA Markers for Severe-Disease-Associated Strains of Clostridium difﬁcile (cid:1) † (2011) (0)
1216Restriction endonuclease analysis of stool culture isolates from children with multiple episodes of Clostridium difficile infection demonstrates some unexpectedly long intervals to relapse with the initial infecting strain (2014) (0)
Stopping an Epidemic of Clostridium difficile Diarrhea (1994) (0)
Adult Clostridium difficile (2006) (0)
Strategies to prevent Clostridioides difficile infections in acute-care hospitals: 2022 Update (2023) (0)
DNA Fingerprinting byPulsed Field GelElectrophoresis and Ribotyping ToDistinguish Pseudomonas cepacia Isolates froma Nosocomial Outbreak (1991) (0)
Incidence and Outcome of Clostridium difficile Infection-Beware of Strain Type and Diagnostic Tests. (2020) (0)
Meet the Professors (2004) (0)
Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with <named-content content-type='genus-species' xlink:type='simple'>Clostridium difficile</named-content> Infection (2015) (0)
Contributors (2015) (0)
Fat Embolism. (1981) (0)
Symptomless colonisation by Clostridium difficile and risk of diarrhoea (1998) (0)
Differential immunodetection of toxin B from highly virulent C. difficile BI/NAP-1/027 1 (2015) (0)
1 Comparative genome analysis and global phylogeny of the toxin variant 1 Clostridium difficile PCR Ribotype 017 reveals the evolution of two independent 2 sub-lineages. 3 (2016) (0)
221. Assessment and Proposed Revision of Clinical Trial Clostridioides difficile Infection Clinical Response and Outcomes Definitions (2022) (0)
PLEURAL EFFUSION ASSOCIATED WITH VffiAL HEPATITIS (1971) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Dale N. Gerding?

Dale N. Gerding is affiliated with the following schools: